C. elegans model experiments have proven that Lp90 can effectively reduce fat accumulation and has potential efficacy in preventing obesity. At the same time, Lp90 can scavenge free radicals, has good superoxide dismutase activity, and has good antioxidant capacity.

Animal experiment results show that BL21 can improve the metabolic syndrome phenotype of mice, including significantly reducing the total cholesterol and triglyceride levels in mouse serum, and reducing the weight of mice. BL21 also scavenges free radicals and has antioxidant activity.

Cell experiment results show that WKB99 can reduce intracellular triglyceride content in HepG2 cells induced by adipogenic differentiation; animal experiment results show that WKB99 can significantly reduce serum alanine aminotransferase activity, total cholesterol, liver alanine aminotransferase and triglyceride content in obese mice, lower blood sugar levels and increase serum HDL cholesterol levels.

Animal experiment results show that LR08 can reduce the levels of total cholesterol, triglycerides and low-density lipoprotein in the blood of obese mice, and increase the levels of high-density lipoprotein, serum insulin and glucagon-like peptide-1, which has the effects of delaying gastric emptying and suppressing appetite, proving that LR08 can regulate glucose and lipid metabolism in the body.

It has good gastrointestinal fluid tolerance, intestinal adhesion ability and antibacterial ability. It can also effectively inhibit pathogenic bacteria such as Shigella flexneri and increase the relative abundance of beneficial bacteria in the intestines of mice.